Vimarsana
Biggest News Aggregation in the World

Page 3 - Thomasj Moore News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Thomasj Moore. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Thomasj Moore Today - Breaking & Trending Today

Be Cautious of Off-Label Use of Stimulants With Other Drugs - Vimarsana News

Be Cautious of Off-Label Use of Stimulants With Other Drugs

It’s an increasingly common trend: U.S. adults who are taking a stimulant medication, together with other drugs that target the central nervous system, such as antidepressants, opioids, and anti-anxiety medications.

Source: webmd.com
Widespread Prescribing of Stimulants With Other CNS Meds - Vimarsana News

Widespread Prescribing of Stimulants With Other CNS Meds

A large proportion of US adults prescribed Schedule II stimulants are simultaneously receiving other CNS agents, including benzodiazepines, opioids, and antidepressants.

Patients Taking Multiple ADHD Drugs with Other Psychiatric Drugs Is Public Health Concern, Researchers Say - Vimarsana News

Patients Taking Multiple ADHD Drugs with Other Psychiatric Drugs Is Public Health Concern, Researchers Say

Another new study found as many as one in four students surveyed at middle schools and high schools reported misusing ADHD drugs in the previous year.

Navy's first Vietnamese admiral survived massacre of his family by man who was executed in 1968 - Vimarsana News

Navy's first Vietnamese admiral survived massacre of his family by man who was executed in 1968

In 1975, around 125,000 Vietnamese refugees fled to the United States after South Vietnam fell to the North Vietnamese forces. One of those refugees was U.S. Navy Rear Adm. Huan Nguyen.

Timely treatment decisions: the promise of surrogate markers - Vimarsana News

Timely treatment decisions: the promise of surrogate markers

The use of surrogate markers to make decisions about a treatment sooner can save lives. But it requires a compromise between waiting 20 years to approve a new treatment and rushing treatment decisions. It should be up to patients, clinicians, researchers, policymakers, and payers to work together to decide on the cost of that compromise effectively.